Timolol
- Generic Name
- Timolol
- Brand Names
- Azarga, Betimol, Combigan, Cosopt, Duotrav, Istalol, Timoptic, Xalacom
- Drug Type
- Small Molecule
- Chemical Formula
- C13H24N4O3S
- CAS Number
- 26839-75-8
- Unique Ingredient Identifier
- 5JKY92S7BR
- Background
Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective agent for the management of conditions such as open-angle glaucoma and hypertension.
- Indication
Ophthalmic timolol is indicated for the treatment of increased intraocular pressure in patients with ocular hypertension or open-angle glaucoma. The oral form of this drug is used to treat high blood pressure. In certain cases, timolol is used in the prevention of migraine headaches.
- Associated Conditions
- Increased Intra Ocular Pressure (IOP), Migraine, Ocular Hypertension, Open Angle Glaucoma (OAG)
Topical Timolol: a Comparison of Surgical Outcomes
- Conditions
- Wound Heal
- Interventions
- Other: Standard Wound Care
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Keith G. LeBlanc, Jr, MD
- Target Recruit Count
- 30
- Registration Number
- NCT05114239
- Locations
- 🇺🇸
Skin Surgery Centre, Metairie, Louisiana, United States
Nebivolol 0.5, 1.0, or Timolol 0.5 Suspension Compared to Timolol 0.5 Solution to Treat Glaucoma/Ocular Hypertension
- Conditions
- Open-Angle GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2021-06-02
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Betaliq, Inc.
- Target Recruit Count
- 226
- Registration Number
- NCT04910100
- Locations
- 🇺🇸
Site 0012, Newport Beach, California, United States
Absorption and Safety of Topical Timolol to Treat Chronic Wounds
- First Posted Date
- 2021-05-26
- Last Posted Date
- 2021-05-27
- Lead Sponsor
- VA Northern California Health Care System
- Target Recruit Count
- 40
- Registration Number
- NCT04903366
- Locations
- 🇺🇸
VA Northern California Health Care System, Mather, California, United States
Interval Intraocular Pressure in Intravitreal Injection Study
- Conditions
- GlaucomaIntraocular Pressure
- Interventions
- First Posted Date
- 2021-04-30
- Last Posted Date
- 2021-04-30
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 64
- Registration Number
- NCT04868175
- Locations
- 🇭🇰
HKSDS Program, Hong Kong, Hong Kong
A Study to Evaluate Safety and Tolerability of QLS-101 in NTG
- Conditions
- Normal Tension Glaucoma (NTG)
- Interventions
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Qlaris Bio, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT04857827
- Locations
- 🇺🇸
Vance Thompson Vision, Sioux Falls, South Dakota, United States
Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).
- Conditions
- Ocular HypertensionPrimary Open Angle Glaucoma
- Interventions
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Qlaris Bio, Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT04830397
- Locations
- 🇺🇸
Dixon Eye Care, Albany, Georgia, United States
Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting
- Conditions
- Ocular Surface DiseasePrimary Open Angle Glaucoma
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- Santen Pharmaceutical (Taiwan) Co., LTD
- Target Recruit Count
- 50
- Registration Number
- NCT04828057
- Locations
- 🇨🇳
Chang-Geng Medical Foundation Linkou Chang-Geng Memorial Hospital, Taoyuan city, Taiwan
Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
- Conditions
- Ocular HypertensionPrimary Open Angle Glaucoma
- Interventions
- Drug: DE-126 Ophthalmic Solution 0.002% QD
- First Posted Date
- 2021-02-08
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Santen Inc.
- Target Recruit Count
- 323
- Registration Number
- NCT04742283
- Locations
- 🇺🇸
Vance Thompson Vision - ND, W. Fargo, North Dakota, United States
🇺🇸Northern New Jersey Eye Institute, South Orange, New Jersey, United States
🇺🇸Black Hills Regional Eye Institute, Rapid City, South Dakota, United States
Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance
- Conditions
- GlaucomaOHT - Ocular Hypertension
- Interventions
- First Posted Date
- 2020-06-02
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Ohio State University
- Target Recruit Count
- 100
- Registration Number
- NCT04412096
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸The Ohio State University, Columbus, Ohio, United States
Evaluation of the Efficacy of Captopril Versus Propranolol and Timolol as a Treatment of Infantile Capillary Hemangioma
- Conditions
- Infantile Hemangioma
- Interventions
- First Posted Date
- 2020-02-28
- Last Posted Date
- 2020-02-28
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 100
- Registration Number
- NCT04288700
- Locations
- 🇪🇬
Vascular malformation clinic of Pediatric Surgery department of Ain Shams University., Cairo, Egypt
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.